Johnson & Johnson (JNJ) announced on Saturday that its bispecific T-cell engager Talvey, when used with Halozyme ...
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD ...
New data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress of the investigational ...
Cullinan Therapeutics shares rose in premarket trading Monday after the company reported that preliminary data showed its experimental T-cell engager produced encouraging clinical responses in lupus ...
Issued on behalf of GT Biopharma, Inc.Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...
As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results